Autolus Therapeutics (AUTL) announces the U.S. FDA has granted marketing approval for Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- FDA approves obecabtagene autoleucel for certain type of ALL
- Autolus Therapeutics to present clinical data updates at ASH 2024
- Autolus Therapeutics presents clinical data on obe-cel treatment
- Autolus Therapeutics Highlights Advances at Life Sciences Conference
- Autolus Therapeutics appoints WIll as Chief Development Officer